Colossal Biosciences
Colossal Biosciences raises $200M Series C at $10.2B valuation
Quick Facts
Colossal Biosciences: Series C Funding Round
Colossal Biosciences has successfully raised $200M in Series C funding, reaching a valuation of $10.2B.
Company Overview
De-extinction and genetic engineering
Funding Details
The Series C round was led by Breyer Capital, with participation from In-Q-Tel, Tony Robbins.
Company Information
- Headquarters: Dallas, TX
- Founded: 2021
- Employees: 150+
- Category: Biotech
Investment
Colossal Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Breyer Capital: Verified investor in Series C
- In-Q-Tel: Verified investor in Series C
- Tony Robbins: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
